Advertisement

PharmacoEconomics

, Volume 3, Issue 6, pp 446–453 | Cite as

Economic and Quality-of-Life Aspects of Treating Small Cell Lung Cancer

  • P. Graham
  • J. Boyages
Leading Article

Keywords

Small Cell Lung Cancer Combination Chemotherapy Autologous Bone Marrow Transplant Utility Coefficient Lung Cancer Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aaronson NK. Assessing the quality of life of patients in cancer clinical trials: common problems and common sense solutions. European Journal of Cancer 28: 1304–1307, 1992CrossRefGoogle Scholar
  2. Barth N, Sferruza A, Akahoshi M, Allen K, Ditmore K. Administration of high dose chemotherapy (HDC) and autologous stem cells (ASC) in the outpatient setting. Abstract. Proceedings of the American Society of Clinical Oncology II: 389, 1992Google Scholar
  3. Bayliss EJ, Trotter JM. The cost of small cell lung cancer (SCLC). Abstract. Cancer Forum 14: 111, 1990Google Scholar
  4. Bergman B, Sullivan M, Sorenson S. Quality of life during chemotherapy for small cell lung cancer. Acta Oncologica 30: 947–957, 1991PubMedCrossRefGoogle Scholar
  5. Carney DN. The biology of lung cancer. In Nunn (Ed.) European School of Oncology monographs: current topics in lung cancer, Springer-Verlag, Berlin Heidelberg, 1991Google Scholar
  6. Casliglione M, Bacchi M, Metzger U, Senn HJ. Quality of life in melaslic breast cancer: comparing perceptions of patients and nurses. Abstract. Proceedings of the American Society of Clinical Oncology II: 54, 1992Google Scholar
  7. Clark PI, Slevin ML. Small cell lung cancer: single agents revisited. Respiratory Medicine 3: 381–382, 1989CrossRefGoogle Scholar
  8. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 325: 164–170, 1991PubMedCrossRefGoogle Scholar
  9. Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in canter patients. Journal of Clinical Oncology 7: 959–968, 1989PubMedGoogle Scholar
  10. Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, et al. A randomised trial of as planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 64: 566–572, 1991PubMedCrossRefGoogle Scholar
  11. Evans DB. What is cost-effectiveness analysis. Medical Journal of Australia 153(Suppl.): 7–9, 1990aGoogle Scholar
  12. Evans DB. Principles involved in costing. Medical Journal of Australia 153(Suppl.): 10–12, 1990bGoogle Scholar
  13. Fayers P. Quality-of-life assessments in small cell lung cancer. PharmacoEconomics 2: 181–188, 1992PubMedCrossRefGoogle Scholar
  14. Ganz PA, Haskell CM, Figlin A, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky Performance Status and the Functional Living Index-Cancer. Cancer 61: 849–856, 1988PubMedCrossRefGoogle Scholar
  15. Gelber RD, Goldhirsch A. A new end point for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. Journal of Clinical Oncology 4: 1772–1779, 1986PubMedGoogle Scholar
  16. Glasziou PP, Simes J, Gelber RD. Quality-adjusted survival analysis. Statistics in Medicine 9: 1259–1276, 1990PubMedCrossRefGoogle Scholar
  17. Goldhirsch A, Gelber RD, Simes J, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. Journal of Clinical Oncology. 7: 36–44, 1989PubMedGoogle Scholar
  18. Goldman L. Cost awareness in medicine. In Wilson et al. (Eds) Harrison’s principles of internal medicine, pp. 11–15, McGraw-Hill, New York, NY, USA, 1990Google Scholar
  19. Goodwin PJ, Feld R, Evans WK., Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomised trial in small-cell lung cancer. Journal of Clinical Oncology 6: 1537–1547, 1988PubMedGoogle Scholar
  20. Gotay CC, Korn EC, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. Journal of the National Cancer Institute 84: 575–578, 1992PubMedCrossRefGoogle Scholar
  21. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. American Journal of Medicine 40: 360–367, 1969Google Scholar
  22. Hanks GE. The crisis in health care cost in the United States: some implications for radiation oncology. International Journal of Radiation, Biology and Physics 23: 203–206, 1992CrossRefGoogle Scholar
  23. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. Journal of the American Medical Association 267: 2055–2061, 1992PubMedCrossRefGoogle Scholar
  24. Houtts PS, Lipton A, Harvey HA, Martin B, Simmonds MA et al. Non medical costs to patients and their families associated with outpatient chemotherapy. Cancer 53: 2388–2392, 1984CrossRefGoogle Scholar
  25. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung; a randomised study. Journal of Clinical Oncology 5: 1864–1873, 1987PubMedGoogle Scholar
  26. Hyde L, Wolf J, McCracken S, Yesner R. Natural course of inoperable lung cancer. Chest 64: 309–312, 1973PubMedCrossRefGoogle Scholar
  27. Johnson PWM, Seymour MT, Waines A, Squires L, Slevin ML. Etoposide as a single agent in small cell lung cancer (SCLC): as good as combination chemotherapy? Proceedings of the American Society of Clinical Oncology 11: 291, 1992Google Scholar
  28. Langlands A. Cost effectiveness or catch 22? Medical Journal of Australia 157: 6–7, 1992PubMedGoogle Scholar
  29. Langlands AO. The evaluation of the results of cancer therapy; treatment utility. Australian and New Zealand Journal of Surgery 51: 10–12, 1981PubMedCrossRefGoogle Scholar
  30. Lowenbraun S, la Rocca RV. Neutrophil count-directed G-CSF administration following chemotherapy. Abstract. Proceedings of the American Society of Clinical Oncology II: 401, 1992Google Scholar
  31. McGivney WT. Proposal for assuring technology competency and leadership in medicine. Journal of the National Cancer Institute 84: 742–743, 1992PubMedCrossRefGoogle Scholar
  32. McKillop WJ, Gard GK, O’Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small-cell lung cancer. British Journal of Cancer 54: 661–667, 1986CrossRefGoogle Scholar
  33. McVie JG. Counting costs of care. Journal of Clinical Oncology 6: 1529–1531, 1988PubMedGoogle Scholar
  34. Medical Research Council Lung Cancer Working Party. Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the Medical Research Council Lung Cancer Working Party. British Journal of Cancer 64: 299–306, 1991Google Scholar
  35. Medical Research Council Lung Cancer Working Party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Respiratory Medicine 83: 51–58, 1989aGoogle Scholar
  36. Medical Research Council Lung Cancer Working Party. Controlled trial of twelve vs six courses of chemotherapy in the treatment of smali-cell lung cancer. British Journal of Cancer 59: 584–590, 1989bGoogle Scholar
  37. Minna JD, Pass H, Glatstein E, Ihde DC. Cancer of the Lung. In De Vita (Ed.) Cancer principles and practice of oncology, 3rd ed., JB Lippincott Co., Philadelphia, 1989Google Scholar
  38. Osterlind K, Anderson PK. Prognostic factors in small cell lung cancer: multivariate analysis based on 778 patients treated with chemotherapy with or without irradiation. Cancer Research 46: 4189–4194, 1986PubMedGoogle Scholar
  39. Richardson GE, Venzon DJ, Steinberg SM, Phelps R, Frame JN, et al. An algorithm for staging patients with small cell lung cancer (SCLC) can save 40% of the initial evaluation costs. Abstract. Proceedings of the American Society of Clinical Oncology 10: 242, 1991Google Scholar
  40. Rosenthal MA, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, et al. The cost of treating small cell lung cancer. Medical Journal of Australia 156: 605–610, 1992PubMedGoogle Scholar
  41. Sheehan RG, Balaban EP, Cox JV, Frenkel EP. The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer. Journal of Clinical Oncology 8: 2047–2053, 1990PubMedGoogle Scholar
  42. Silverberg E. Cancer statistics, 1988. CA 38: 5–22, 1988Google Scholar
  43. Souadjian JV, Bhaskar B, Briscoe KE, Opfell RW, Agopian JM. Home chemotherapy (CT): safety and cost-effectiveness. Proceedings of the American Society of Clinical Oncology 11: 410, 1992Google Scholar
  44. Spiegelman D, Mauer LH, Ware JH, Perry MC, Chatnnian P, et al. Prognostic factors in small cell lung carcinoma of the lung: an analysis of 1521 patients. Journal of Clinical Oncology 7: 344–354, 1989PubMedGoogle Scholar
  45. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small-cell carcinoma of the lung? A meta-analysis. Journal of Clinical Oncology 10: 890–895, 1992PubMedGoogle Scholar
  46. Wolf M, Prtsch M, Drings P, Hans K, Scbroeder M, et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomised trial of 321 patients. Journal of Clinical Oncology 9: 614–624, 1991PubMedGoogle Scholar
  47. Zelen M. Keynote address on bioslatistics and data retrieval. Cancer Chemotherapy Reports 4(part 3): 31–42, 1973Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • P. Graham
    • 1
  • J. Boyages
    • 1
  1. 1.Department of Radiation OncologyWestmead HospitalWestmeadAustralia

Personalised recommendations